Theravance Biopharma Inc TBPH

NAS: TBPH | ISIN: KYG8807B1068 30/04/2025

9,770 USD (+2,84%)

(+2,84%) 30/04/2025

Grafiek Theravance Biopharma Inc

Grafiek Theravance Biopharma Inc

1 dag1d 2,84%
1 week1w 2,41%
1 maand1m 8,31%
3 maanden3m 3,17%
6 maanden6m 18,00%
1 jaar1j 10,52%
5 jaar5j -63,48%

donderdag 8 mei 2025, 22:00

Kwartaalcijfers (1ste kwartaal)

Theravance Biopharma Inc in het nieuws

Toon enkel gratis nieuws

28 april 2025 · Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress · Persbericht

24 april 2025 · Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 · Persbericht

7 april 2025 · Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting · Persbericht

31 maart 2025 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

27 maart 2025 · Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology · Persbericht

27 augustus 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

5 augustus 2024 · Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

25 juli 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

22 juli 2024 · Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 · Persbericht

13 mei 2024 · Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update · Persbericht

Profiel Theravance Biopharma Inc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

CEO: Rick Winningham

Werknemers: 270

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe